Sector News

Glenmark takes aim at Celgene's Abraxane with complex generic deal

September 23, 2016
Life sciences

Complicated drug formulations are generally viewed as a barrier to generic competition, but that is not stopping India’s Glenmark from placing Celgene’s cancer drug Abraxane in its sights.

Glenmark has just signed a licensing deal with U.S. firm Particle Sciences for a generic version of Abraxane–an albumin-bound injectable formulation of paclitaxel–and says it plans to start filing the generic in 2019, starting with the U.S. market.

Used for pancreatic, breast and lung cancer, Abraxane is still a big earner for Celgene with sales rising 14% to $967 million last year, despite increasing competition from new breast and lung cancer therapies. Two-thirds of sales–some $654 million–came from the U.S.

The Indian drugmaker said the deal with Particle Sciences is a step forward in its plans to develop complex generics such as particulate injections–in which active drugs are bound to micro- and nanoparticle carriers. Complex generics cost more and take longer to develop, but tend to give a higher return on investment than simple generics as they generally face less competition.

Particle Sciences, a subsidiary of Lubrizol LifeSciences, will be responsible for developing the generic for Glenmark in return for unspecified milestones and royalties on sales should the drug reach the market.

In the U.S., a launch will likely depend on the outcome of patent litigation, as Celgene is claiming exclusivity on its drug out to 2023. It has already filed a lawsuit against Allergan, which filed for approval of an Abraxane clone in March.

“This is a challenging product to develop and we expect it to remain a limited competition opportunity,” commented Robert Matsuk, president of Glenmark’s North American division.

Celgene is still banking on significant growth for Abraxane, thanks to a steady stream of new indications, and has said the drug could hit $1.5 billion in sales in the next couple of years. It is starting to move into early-stage breast cancer, with an EU filing due shortly, and is in mid-stage clinical testing for colorectal cancer, melanoma, and head and neck cancer, among other solid tumors.

It is also a key component of Celgene’s efforts to develop combination therapies for cancer. Earlier this year the company reported positive results with the drug in combination with Roche’s PD-L1 inhibitor Tecentriq in triple-negative breast cancer, a form of the disease which has few options at the moment.

Last year, Celgene was denied a patent on Abraxane in India, where the drug is sold by partner Biocon, opening the door for the launch of generic rivals.

Natco was selling a generic version of the drug called Albupax in India a few years ago, but withdrew it from the market after a regulatory review concluded its quality was substandard. Since then Cipla, Panacea Biotech, and Fresenius Kabi have entered the market with their own versions of Abraxane.

By Phil Taylor

Source: Fierce Pharma

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.